BARDA grants $43.2 million to Sanofi Pasteur for Zika

27 September 2016

Sanofi Pasteur, the vaccines unit of French pharma major Sanofi (Euronext: SAN), is to receive $43.2 million from the US Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR), to develop a Zika virus vaccine.

Under the contract through June 2022, ASPR’s Biomedical Advanced Research and Development Authority (BARDA) is providing funding and technical assistance to support the advanced development of an inactivated vaccine candidate to prevent the Zika virus infection and associated devastating birth defects.

The development of this vaccine has been started at the US Department of Defense’s Walter Reed Army Institute of Research (WRAIR).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK